Krishna Institute of Medical Sciences Ltd
Financial Results for Q1 2026-27
RESULTS
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 03 Aug 2026, 06:33 PM IST · BSE ID: 1af31395-1ccc-4ea1-bfcf-c0448305c62e
View Original BSE Filing (PDF)
💡
In Simple Terms
The company released its quarterly earnings, approved significant loan facilities for group entities, and greenlit agreements for new partnerships.
🤖 AI Summary
- Board approved Q1 FY27 unaudited standalone and consolidated financial results as of June 30, 2026.
- Approved to advance loans up to Rs. 650 Crores to group entities, subject to shareholder approval.
- Approved extending a loan of up to ₹25 crore to KIMS Hospital Enterprises Private Limited, a material subsidiary.
- Considered and approved draft O&M agreement and Call Option Agreement with Golden Lan Solutions and Sarwottam Healthcare.
- Standalone Profit for the period (Q1 FY27) was Rs. 688 million, with basic EPS of Rs. 1.66.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q1 FY27 Standalone)
4836 million
Profit for the period (Q1 FY27 Standalone)
688 million
Basic Earnings per share (Q1 FY27 Standalone)
1.66 Rs.
Loan facility to group entities (proposed)
650 Crores
Loan to KIMS Hospital Enterprises Private Limited
25 crore
QIP funds raised (net of expenses)
15,000 million
🏢 How This Affects the Company
The approval of O&M and Call Option Agreements indicates potential expansion or operational changes through new partnerships, which could impact service delivery and market reach. The extension of loans to group entities may support their growth initiatives.
The approved Rs. 650 Crores loan facility to group entities and ₹25 crore loan to a material subsidiary will impact the company's cash flow and inter-company financing structure. Funds raised via QIP (Rs. 15,000 million net of expenses) are being utilized, with balances temporarily invested.
The O&M agreement, once executed, could lead to changes in operational management for certain facilities or services, potentially streamlining operations or expanding managed healthcare services.
The approval of significant loan facilities to group entities (Rs. 650 Crores) introduces financial risk related to inter-company lending, contingent on the financial health and operational performance of the borrowing entities. Shareholder approval is required for the larger loan facility.
👥 What This Means For Shareholders
✅
Action Required
Shareholders must review the upcoming general meeting notice to vote on the special resolution for the Rs. 650 Crores loan facility.
👤
Who Is Affected
All shareholders are affected by the proposed loan facility to group entities, as it involves the company's capital allocation and potential financial risk exposure. Promoters and promoter group entities are also participating in convertible warrants issuance.
🔍
Management Signal
Management intends to support group entity growth through significant loan facilities and explore new operational partnerships, while also utilizing capital from the recently completed QIP.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Shareholder meeting for approval of Rs. 650 Crores loan facility to group entities.
Execution of definitive O&M and Call Option Agreements with Golden Lan and Sarwottam Healthcare.
Consolidated financial results for Q1 FY27, once publicly available with full details.
MEDIUM RISK
Significant inter-company loan approvals present a financial risk depending on the performance of recipient entities; shareholder approval is pending.
💡 Investor Takeaway
Krishna Institute of Medical Sciences Ltd reported Q1 FY27 standalone profit of Rs. 688 million. The board approved a Rs. 650 Crores loan facility to group entities, pending shareholder approval, and a ₹25 crore loan to a material subsidiary, alongside considering new O&M agreements.
⚖️ Strengths & Concerns
✅ Positives
- Standalone Profit for the period for Q1 FY27 reached Rs. 688 million, indicating profitability in the initial quarter.
- The company successfully completed a Qualified Institutions Placement (QIP) raising Rs. 15,000 million (net of expenses) by 30 June 2026, strengthening capital base.
⚠️ Concerns
- Approval for advancing loans up to Rs. 650 Crores to group entities is subject to shareholder approval, introducing an approval contingency.
- The financial results indicate that the consolidated figures are not provided in the publicly available portion of the filing, limiting comprehensive financial assessment.
📅 Company Track Record
Previous filings for Krishna Institute of Medical Sciences Ltd on 2026-08-03 also noted Q1 FY27 standalone profit of Rs. 688 million and the approval of the Rs. 650 Crores loan facility to group entities, affirming these decisions.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Krishna Institute of Medical Sciences Ltd's standalone profit in Q1 FY27?
Krishna Institute of Medical Sciences Ltd reported a standalone profit of Rs. 688 million for the first quarter ended June 30, 2026.
What loan facilities were approved by the board of Krishna Institute of Medical Sciences Ltd?
The board approved advancing loans up to Rs. 650 Crores to group entities, subject to shareholder approval, and a separate loan of up to ₹25 crore to KIMS Hospital Enterprises Private Limited.
What was the basic earnings per share (EPS) for Krishna Institute of Medical Sciences Ltd in Q1 FY27?
The basic earnings per share for Krishna Institute of Medical Sciences Ltd in Q1 FY27 was Rs. 1.66.
What agreements did Krishna Institute of Medical Sciences Ltd's board consider and approve?
The board considered and approved the DRAFT O&M agreement and Call Option Agreement with Golden Lan Solutions Private Limited and Sarwottam Healthcare Private Limited.
Questions based on this BSE filing only. For information purposes.